These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15964103)

  • 1. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
    Nolan SM; Surman SR; Amaro-Carambot E; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(39):4765-74. PubMed ID: 15964103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2006 Mar; 24(14):2674-84. PubMed ID: 16364511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
    Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
    Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Newman JT; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(38):4631-46. PubMed ID: 15951066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
    Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
    Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Surman SR; Durbin AP; Collins PL; Murphy BR
    Virology; 2000 Jun; 272(1):225-34. PubMed ID: 10873765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development.
    Witko SE; Kotash CS; Nowak RM; Johnson JE; Boutilier LA; Melville KJ; Heron SG; Clarke DK; Abramovitz AS; Hendry RM; Sidhu MS; Udem SA; Parks CL
    J Virol Methods; 2006 Jul; 135(1):91-101. PubMed ID: 16569439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIV-3 vaccine National Institutes of Health/Aviron.
    Jones T
    Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
    Greer CE; Zhou F; Goodsell A; Legg HS; Tang Z; zur Megede J; Uematsu Y; Polo JM; Vajdy M
    Scand J Immunol; 2007 Dec; 66(6):645-53. PubMed ID: 17944814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3.
    Haller AA; MacPhail M; Mitiku M; Tang RS
    Virology; 2001 Sep; 288(2):342-50. PubMed ID: 11601905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.
    Greer CE; Zhou F; Legg HS; Tang Z; Perri S; Sloan BA; Megede JZ; Uematsu Y; Vajdy M; Polo JM
    Vaccine; 2007 Jan; 25(3):481-9. PubMed ID: 17052811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
    Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
    Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
    Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
    McAuliffe JM; Surman SR; Newman JT; Riggs JM; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2029-36. PubMed ID: 14747567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
    J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
    Slobod KS; Shenep JL; Luján-Zilbermann J; Allison K; Brown B; Scroggs RA; Portner A; Coleclough C; Hurwitz JL
    Vaccine; 2004 Aug; 22(23-24):3182-6. PubMed ID: 15297072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.